Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1770 - Transdermal granisetron for the prevention of chemotherapy-induced nausea and vomiting in metastatic colorectal cancer patients with high risk of bowel obstruction treated with temozolomide


09 Oct 2016


Poster display


Maria Alessandra Calegari


Annals of Oncology (2016) 27 (6): 497-521. 10.1093/annonc/mdw390


M.A. Calegari1, S. Monterisi1, A. Orlandi1, A. Inno2, R. Barile1, S. Corallo1, C. Di Dio1, V. Zurlo1, M. Basso1, A. Cassano1, C. Barone1

Author affiliations

  • 1 Medicina Interna - U.o.c. Di Oncologia Medica, Policlinico Universitario A. Gemelli, 00168 - Roma/IT
  • 2 Medical Oncology, Ospedale S.Cuore, 37024 - Negrar/IT


Abstract 1770


Temozolomide (TMZ) showed efficacy in patients with refractory metastatic colorectal cancer (mCRC) and MGMT promoter methylation. As moderately emetogenic chemotherapy, TMZ requires administration of 5HT3 antagonists for chemotherapy-induced nausea and vomiting (CINV) prevention. Both TMZ and 5HT3 antagonists could cause constipation; besides mCRC patients might have a high risk of bowel obstruction due to disease features (adhesions, local relapses and peritoneal carcinomatosis) and use of opioids. In an ongoing phase II trial we performed an exploratory analysis to compare efficacy and safety of two antiemetic regimens with different risk of constipation.


32 patients with refractory MGMT hypermethylated mCRC receiving TMZ (200 mg/m2/day on days 1-5 every 4 weeks) were assigned with a ratio of 2:1 to oral metoclopramide (10 mg PO TID on days 1-5) or transdermal granisetron (Sancuso®) (3.1 mg/24 h on days 1-7). Patient filled in a diary reporting nausea, emetic episodes and constipation. Adverse events were recorded and scored according to CTCAE. A two-sided Fisher's exact test was used to evaluate differences in nausea, vomiting, constipation and bowel obstruction (p-value


From July 2013 to January 2016, 22 patients received metoclopramide and 10 patients granisetron. Patients' characteristics were well balanced between the two groups both for previous abdominal surgery and opioid therapy, whereas peritoneal carcinomatosis rate was higher in patients receiving granisetron (60 vs 13.6%). The incidence of CINV was statistically significant lower in the granisetron group both for nausea (0 vs 95%, p 


Our results showed that transdermal granisetron is more effective in CINV prevention and as safe as oral metoclopramide in terms of rate of constipation and bowel obstruction in patients affected by mCRC receiving TMZ. Thus transdermal granisetron might represent a standard in CINV prevention in this setting.

Clinical trial identification

EudraCT 2012-002766-13

Legal entity responsible for the study

Fondazione Policlinico "A. Gemelli", Rome


Fondazione Policlinico "A. Gemelli", Rome


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings